middle.news
Vectus Biosystems Advances Clinical Trials and Secures Strong Cash Position
6:15pm on Sunday 1st of June, 2025 AEST
•
Biotechnology
Read Story
Vectus Biosystems Advances Clinical Trials and Secures Strong Cash Position
6:15pm on Sunday 1st of June, 2025 AEST
Key Points
Completed Phase Ia/Ib clinical trials for VB0004 with no significant adverse events
Cash on hand increased to $810,000 after receiving a $977,000 R&D tax refund
Operating costs significantly reduced to extend cash runway
Ongoing licensing and partnership discussions led by C14 Consulting Group
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Vectus Biosystems (ASX:VBS)
OPEN ARTICLE